Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy
Journal of Muscle Research and Cell Motility · 2025
DOI: 10.1007/s10974-024-09688-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Muscle Research and Cell Motility, 2025. Verfasst von Katarzyna Chwalenia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Developmental and Regenerative Medicine, University of Oxford, IMS-Tetsuya Nakamura Building, Old Road Campus, Roosevelt Dr, Headington,…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Oligonucleotides, Antisense, Exons, Genetic Therapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Clarendon Fund.
Abstract (Originalsprache)
Recent years have seen enormous progress in the field of advanced therapeutics for the progressive muscle wasting disease Duchenne muscular dystrophy (DMD). In particular, four antisense oligonucleotide (ASO) therapies targeting various DMD-causing mutations have achieved FDA approval, marking major milestones in the treatment of this disease. These compounds are designed to induce alternative splicing events that restore the translation reading frame of the dystrophin gene, leading to the generation of internally-deleted, but mostly functional, pseudodystrophin proteins with the potential to compensate for the genetic loss of dystrophin. However, the efficacy of these compounds is very limited, with delivery remaining a key obstacle to effective therapy. There is therefore an urgent need for improved ASO technologies with better efficacy, and with applicability to a wider range of patient mutations. Here we discuss recent developments in ASO therapies for DMD, and future prospects with a focus on ASO chemical modification and bioconjugation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Developmental and Regenerative Medicine, University of Oxford, IMS-Tetsuya Nakamura Building, Old Road Campus, Roosevelt Dr, Headington, Oxford, OX3 7TY, UK.
- Department of Paediatrics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK.
- MDUK Oxford Neuromuscular Centre, Oxford, OX3 7TY, UK.
- Institute of Developmental and Regenerative Medicine, University of Oxford, IMS-Tetsuya Nakamura Building, Old Road Campus, Roosevelt Dr, Headington, Oxford, OX3 7TY, UK. thomas.roberts@idrm.ox.ac.uk.
- Department of Paediatrics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK. thomas.roberts@idrm.ox.ac.uk.
- MDUK Oxford Neuromuscular Centre, Oxford, OX3 7TY, UK. thomas.roberts@idrm.ox.ac.uk.
ORCID-Profile: Matthew J A Wood, Thomas C Roberts
Förderung
- Medical Research Council
- Clarendon Fund
Zitieren
APA
Chwalenia, K., Wood, M. J. A., & Roberts, T. C. (2025). Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy. Journal of Muscle Research and Cell Motility. https://doi.org/10.1007/s10974-024-09688-2
Vancouver
Chwalenia K, Wood MJA, Roberts TC. Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy. Journal of Muscle Research and Cell Motility. 2025. doi:10.1007/s10974-024-09688-2
BibTeX
@article{Chwalenia2025,
author = {Chwalenia, Katarzyna and Wood, Matthew J A and Roberts, Thomas C},
title = {Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy},
journal = {Journal of Muscle Research and Cell Motility},
year = {2025},
doi = {10.1007/s10974-024-09688-2}
}
EUVIMED